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Abstract
Adult neurogenesis is restricted to specific brain regions. Although involved in the continuous supply of interneurons for
the olfactory function, the role of neural precursors in brain damage-repair remains an open question. Aiming to in vivo
identify endogenous neural precursor cells migrating towards a brain damage site, the monoclonal antibody Nilo2
recognizing cell surface antigens on neuroblasts, was coupled to magnetic glyconanoparticles (mGNPs). The Nilo2-mGNP
complexes allowed, by magnetic resonance imaging in living animals, the in vivo identification of endogenous neural
precursors at their niche, as well as their migration to a lesion site (induced brain tumor), which was fast (within hours) and
orderly. Interestingly, the rapid migration of neuroblasts towards a damage site is a characteristic that might be exploited to
precisely localize early damage events in neurodegenerative diseases. In addition, it might facilitate the study of
regenerative mechanisms through the activation of endogenous neural cell precursors. A similar approach, combining
magnetic glyconanoparticles linked to appropriate antibodies could be applied to flag other small cell subpopulations
within the organism, track their migration, localize stem cell niches, cancer stem cells or even track metastatic cells.
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Introduction
In spite of new advances in understanding the biology of
embryonic stem cells and induced pluripotent stem cells, tissue-
specific stem cells remain the most promising cells for regenerative
medicine, due to their ability to self-renew and differentiate into
the distinct cell types that constitute a particular tissue. Neural
precursors are mainly localized in the subventricular zone (SVZ) of
the lateral ventricles and the subgranular zone (SGZ) of the
hippocampus dentate gyrus [1–4]. In the adult SVZ, neural stem
cells (B1 astrocytes) generate through different intermediates,
neuroblasts and glial precursors, which differentiate into neurons
and glia, respectively [1,5–7]. It is known that neurogenesis in the
adult brain plays an important role maintaining the homeostasis,
such as in the olfactory bulb where a continuous supply of
migrating neuroblasts is required for the generation of periglo-
merular interneurons. Indeed, neuroblasts migrate from the SVZ
to the olfactory bulb through the rostral migratory stream (RMS)
[8–12] as recently confirmed by magnetic resonance imaging
(MRI) analyses of migrating endogenous neural cells with in situ
endocytosed nanoparticles [13–17]. In addition, experiments using
in vivo BrdU-labeled cells [18–21], or in vitro labeled cells
subsequently grafted in a recipient brain [22–33] have shown
that in response to brain insults, cells migrate towards the lesion
site. MRI combined with contrast agents has been widely used as a
noninvasive technique to study cell migration of grafted cells with
an efficient labeling without impairment on cell survival,
proliferation, self-renewal or multipotency [34]. Taken together,
these data suggest migration of neural cells to damage sites,
although without direct evidence for migration of any particular
endogenous progenitor subpopulation, and allow envisaging the
possibility that in response to brain damage there is neurogenesis
in the adult brain.
To in vivo track an endogenous neural cell subpopulation
migrating towards a brain damage site, we took advantage of the
monoclonal antibody Nilo2, recognizing live neuroblast cells [35],
which was coupled to recently developed magnetic glyconano-
particles (mGNPs) [36]. The Nilo2-mGNP conjugates were
suitable for magnetic resonance imaging detection and were used
to analyze in vivo neuroblast cell niches, as well as the migration of
specifically labeled endogenous neuroblasts from their niche
towards an astrocytoma lesion site.
Materials and Methods
Animals
Experiments were performed in compliance with the European
Union and Spanish laws (Council Directive 86/609/EEC) and
approved by the Committee of Animal Experimentation of the
CSIC. For these experiments 6–8 week old FVB or C57Bl/6
animals, bred and housed in our animal facility under standard
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conditions were used. All surgery was performed under anesthesia,
and efforts were made to minimize suffering.
Antibodies
Nilo2 mAb was generated by the fusion of hamster B cells and
the mouse myeloma X63Ag8, as described [35]. Purified Nilo2
was from Immunostep Inc. (Salamanca, Spain). Commercial
antibodies and other reagents are described in Table 1.
Synthesis and Characterization of the Protein G-magnetic
Glyconanoparticles (mGNPs)
Water soluble magnetic glyconanoparticles consisting on a 4 nm
magnetic core covered with a 1 nm gold shell coated with
carbohydrates and an amphiphilic linker with an end-position
carboxyl group were prepared and characterized as previously
described [36]. Covalent immobilization through the carbonyl
groups of a recombinant and commercially available protein G
enables capture of IgG antibodies on the nanoparticles [37,38].
Lyophilized nanoparticles (1.0 mg) were dissolved in 1 ml of
PBS. The carboxyl groups were activated by adding a solution of
N-ethyl-N9-(3-dimethylaminopropyl) carbodiimide hydrochloride
(EDC) (40 mg, 0.21 mmol) and N-hydroxysuccinimide (NHS)
(36 mg, 0.31 mmol). This mixture was shaken for 90 min, diluted
to 3 ml of PBS and shaken for 3 hours at 10uC with protein G
(161 ml, 1 mg/ml in PBS, Southern Biotech) on a 5:1 (protein G:
nanoparticles) ratio. The mixture was immediately centrifuged at
14000 6 g for 90 min at 4uC. Uncoupled protein G was
eliminated following washes in PBS. The resulting pellet was
suspended in 25 mM Tris pH 9, 100 mM glycine. Protein G-
glyconanoparticles (mGNPs) were characterized by MALDI-TOF
spectrometry. The amount of coupled protein G was quantified by
the Bradford method. Iron content was evaluated by induced
coupled plasma optical atomic spectroscopy (ICP-OAS) estimating
that 1.5 mg mGNPs contained 48 mg Fe. The relaxivity values r2
of the mGNPs (137 mM21s1 in PBS at 37uC, 1.4 Teslas) did not
change in comparison to the precursor glyconanoparticles [36].
Core size of the protein G-glyconanoparticles, estimated from the
TEM micrographs, was the same as those of the glyco-ferrites.
T2* estimation of mGNPs was calculated from phantom data.
Phantoms were prepared on agar supplemented with copper
sulfate with different concentrations of iron from dextran coated
commercial nanoparticles EndoremTM (Guerbert Laboratories) or
protein G functionalized nanoparticles (mGNPs). Measurements
were carried out with a Bruker Biospec 70/20 scanner (7T) using a
linear coil resonator, employing a multiple gradient echo sequence
(parameters: TR 1500 ms, TE 4 to 53 ms, echo spacing 7 ms),
from where the T2* map was calculated. Similar ROIS were
traced on each image and their mean values were normalized to
Table 1. Commercial antibodies used in flow cytometry, immunocytochemistry, immunohistochemistry and immunoblotting.
PRIMARY ANTIBODIES
Antibody Host Source Clone or Cat. # Ab Dilution
SOX2 Rabbit, polyclonal Chemicon AB5603 1:400
DCX Goat, polyclonal Santa Cruz Biotech. Sc-8066 1:200
PSA-NCAM Mouse, monoclonal Chemicon MAB5324 1:400
PSA-NCAM Mouse, monoclonal (IgM) Abcys online AbC0019 1:1000
CD4 Rat, monoclonal BD Pharmingen 553043 1:200
CD4-FITC Rat, monoclonal BD Pharmingen 553055 1:200
CD8-FITC Rat, monoclonal BD Pharmingen 553031 1:200
CD11b Rat, monoclonal BD Pharmingen 553308 1:100
GFAP Rabbit, polyclonal Neomarkers RB-087-A1 1:200
hup53 Rabbit, polyclonal Cell Signalling Tech. 2521S –
CD3e Hamster, monoclonal BD Pharmingen 553058 –
SECONDARY ANTIBODIES AND REAGENTS
Antibody Host Source Clone or Cat. # Ab Dilution
Anti-hamster IgG-HRP Mouse BD Pharmingen 554012 1:5000
Anti-hamster-FITC Mouse BD Pharmingen 554011 1:100
Anti-mouse IgG-Texas Red Goat Molecular Probes T-862 1:400
Anti-mouse IgM A546 Goat Invitrogen A-21045 1:400
Anti-rat Alexa Fluor 647 Goat Invitrogen A-21247 1:400
Anti-rabbit IgG-Cy3 Goat Jackson ImmunoResearch 111-165-003 1:400
Anti-goat 594 Chicken Invitrogen A21468 1:400
Anti-hamster biotin Mouse BD Pharmingen 550335 1:100
Streptavidin Alexa Fluor 647 – Invitrogen S32357 1:400
Streptavidin Alexa Fluor 488 – Invitrogen S32354 1:400
Streptavidin Texas Red – Invitrogen S872 1:400
doi:10.1371/journal.pone.0044466.t001
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the background value. These values were represented versus iron
concentration.
Nilo2 Binding to Magnetic Nanoparticles
Protein G-magnetic glyconanoparticles (mGNPs) (100 mg) were
incubated 5 h at 4uC with Nilo2 mAb (135 mg) in 0.1 M glycine
buffer pH 9.0 on a final volume of 50 ml. After three PBS washes,
nanoparticles were isolated by centrifugation and solubilized in
30 ml of PBS. The amount of Nilo2 mAb bound to the mGNPs
was determined by western blot using SDS-PAGE and a
secondary antibody antiHa-HRP (1:5000). Purified Nilo2 mAb
(0.75 mg) was used as standard and different volumes (1–3 ml) of
the Nilo2-mGNPs suspension were loaded corresponding to 3.5–
10.5% of the volume sample. Quantification by densitometry
allowed to estimate that Nilo2-mGNPs contained 0.20 mg/ml
Nilo2 (1.82 mg Nilo2/mg Fe).
Size and morphology of the Nilo2-mGNPs were estimated by
transmission electron microscopy (TEM). Nilo2-mGNPs were
dissolved in 20 mM Tris-HCl pH 7.4, 200 mM NaCl and applied
during 1 min to a carbon-coated Cu-Pd grid with glow-discharge.
After negative staining with 2% uranyl acetate for 40 s, samples
were observed using a JEOL 1230 transmission electron micro-
scope operated at 100 kV.
Neurosphere Preparations and Cell Culture
Neurospheres for in vitro experiments were prepared from the
SVZ of 6- to 8-week old FVB mice or from E13.5 C57Bl/6
olfactory bulbs as described [35]. Alternatively, for in vivo
experiments with grafted cells, GFP+ neurospheres were obtained
from b-actin EGFP transgenic mice (C57Bl/6 background) [39].
CT-2A mouse astrocytoma (gift from Prof. T.N. Seyfried, Boston,
MA, USA), and GFP-CT-2A (gift from A. Martinez, I. Cajal,
CSIC, Madrid, Spain) [40], were grown in RPMI medium, 10%
heat-inactivated fetal bovine serum in 5% CO2 at 37uC and 95%
humidity.
Intracranial Surgery
C57BL/6J mice were anaesthetized intraperitoneally with
100 mg/kg of ketamine and 10 mg/kg of xylacine. The mice
heads were immobilized in a stereotaxic frame and intracranially
injected with 1 ml of Nilo2-mGNPs in the striatum at coordinates
+0.9 mm anterior, +0.75 mm lateral, 22.75 mm ventral from the
bregma point. As control, PBS was used. Brain fixations were
performed on anesthetized mice by transcardiac perfusion with
4% paraformaldehyde (PF) in 0.1 M phosphate buffer (fixation
buffer). Brains were extracted and post-fixed overnight at 4uC in
fixation buffer and cryoprotected in fixation buffer with 30%
sucrose for two days at 4uC before freezing at 280uC. Fixed brains
were cut in cryostat at 25 mm and slices maintained at 220uC in
glycerol/etilenglycol buffer until analyzed.
In vivo identification of Nilo2+ cells in their niches was done
injecting 1 ml of purified Nilo2 (0.25 mg) at stereotaxic coordinates
+0.9 mm anterior, +0.75 mm lateral, 22.75 mm ventral refereed
to bregma point. Mice (n = 4) were perfused 24 h later.
For neurosphere-EndoremTM graft experiments, neurospheres
from E13.5 olfactory bulb embryos were disaggregated and
incubated with EndoremTM nanoparticles (136104 cells with
50 mg/ml Fe or 36104 cells with 5 mg/ml Fe) for 48 h at 37uC.
Collected cells were PBS washed and stereotaxically injected into
the right (2 ml with 46103 cells from low iron content) or the left
(2 ml with 36104 cells from high iron content) lateral ventricles at
positions +0.14 anterior, +/20.75 lateral, 22.25 ventral respect to
bregma point. With these conditions the maximum iron injected
was 0.22 mg Fe in the right or 17 mg Fe in the left lateral ventricles.
Next day, MRI was performedon anesthetized mice (n = 2).
Tumor mice model was generated by intracranial graft of
102226105 CT-2A or GFP-CT-2A cells in 1 ml of PBS at
stereotaxic coordinates +0.1 mm anterior, 22.25 mm lateral,
22.70 mm ventral into the right caudate putamen.
In GFP+-neurosphere graft experiments used to study migration
kinetics of exogenous cells in response to an induced tumor, SVZ
neurospheres (46104 cells) from adult EGFP-transgenic mice
(n = 6) were injected at stereotaxic coordinates +0.14 anterior, +0.6
lateral, 22.25 ventral respect to bregma point (into the right
lateral ventricle). CT-2A cells (16104 cells) were injected into the
left striatum of mice (n = 3) three days later at position +0.1 mm
anterior, 22.25 mm lateral, 22.70 mm to induce a tumor. Mice
were sacrificed next day to analyze the location of GFP+ cells.
Magnetic Resonance Imaging
MRI studies were performed in a Bruker Biospec 70/20 scanner
using a combination of a linear coil (for transmission) with a mouse
head phase array coil (for reception). Animals were anesthetized
with sevofluorane (5% for induction and 2% for maintenance) and
placed in an MRI-adapted stereotaxic holder. Respiration and
body temperature were continuously monitored. MRI acquisition
protocol included an initial flash sequence (repetition time:
100 ms, echo time: 6 ms, field of view: 4 cm, matrix: 1286128)
to center the Field of View (FOV), followed by a shimming
procedure applied to a region of interest covering the head
(FOV = 36262 cm, matrix = 64664664) and based on a Field
Map sequence (TR = 20 ms, TE = 1.43 and 5.42 ms).
As an anatomical reference we used a T2-weighted coronal
image (TR = 2500 ms; TE, 33 ms; a= 180u; FOV = 262 cm;
matrix = 2566256; slice thickness = 0.5 mm) and nanoparticles
were detected and tracked with a 3D multi gradient echo (MGE)
sequence (TR = 200 ms; 8 echoes, TE = 10 to 45 ms; echo
spacing = 5 ms; a= 15u; FOV = 1.661.661.5 cm; ma-
trix = 192696696).
To increase the signal-to-noise ratio (SNR) and improve image
contrast, the different echo images were added (in magnitude). To
display the results, the tumor area was manually segmented on the
T2 scans and spatially aligned with the MGE image.
Figure 1. Identification of neuroblasts with Nilo2 monoclonal antibody. A, Immunohistochemistry of subventricular zone fixed brain
sections double stained for Nilo2 (green) and DCX, PSA-NCAM, SOX2 or GFAP (red) detected by confocal microscopy. B–C, In vivo identification and
characterization of Nilo2+ neural precursors surrounding a tumor induced after injection of CT-2A cells in the left striatum, following intraperitoneal
injection one week latter of purified Nilo2 mAb, which was revealed in tissue sections with a secondary biotinylated anti-hamster Ig antibody and the
appropriate fluorochrome. B. GFP- CT-2A cells were used (GFP+ in green), Nilo2+ cells were identified with streptavidin-Texas Red at low (left) and
high (right) magnification. C, CT-2A cells were injected using the same protocol as in B. Nilo2+ cells in these tissue sections were identified with
streptavidin-A488 (green) simultaneously with the neuroblast markers DCX or PSA-NCAM (red). Confocal microscopy analyses demonstrate that the
Nilo2+ cells surrounding the tumor were DCX+ and PSA-NCAM+, indicating that these cells correspond to neuroblasts. DAPI was used to stain nuclei
(blue). Scale bars: A, 25 mm; B, 100 mm; C, 45 mm; AH, anterior horn.
doi:10.1371/journal.pone.0044466.g001
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Figure 2. Physicochemical and functional characterization of Nilo2-mGNPs. A, Transmission electron microscopy (TEM) of mGNPs (left
panel) or Nilo2-mGNPs (right panel) showing that both remained disperse in aqueous solution. Size distribution of glyconanoparticles before
coupling to protein G was determined from TEM images. Data were fitted to a Gauss distribution (black line) (central panel). B, Phantoms from
In Vivo Tracking of Endogenous Neural Progenitors
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Immunological Analyses and Staining Procedures
Neurosphere adherent cultures were performed on Matrigel
Basement Membrane Matrix Growth Factor Reduced (BD
Pharmingen) pre-coated coverslips with 1:20 dilution in culture
media. Cells were fixed with 4% PF in PBS buffer for 15 min at
RT. Quenching was performed by adding 0.1 M glycine pH 7.4
for 15 min at RT. After three PBS washes, blocking was
performed by incubating the coverslips with 10% mouse serum
in PBS during 1 h at RT. Fixed cells were incubated overnight
with Nilo2-nanoparticles (5 ml/well) mAb at 4uC. After three PBS
washes, cells were incubated with the secondary antibody (anti-
Ha-FITC 1:100, or anti-Ha-Cy5.5 1:500) for 1 h.
To assess whether MRI signals corresponded to labeled
neuroblasts, mouse brains from animals used in MRI analyses
were fixed and cryopreserved for cryostat sectioning in a parallel
plane to that of axial MR imaging. Serial 20–25 mm thick frozen
sections were collected through the entire mouse brain. Anatom-
ical landmarks such as corpus callosum, anterior commisure of the
brain and lateral ventricles opening and shape, were used for the
spatial alignment of MRI and immunohistochemical sections.
Brain sections of mice intracranially injected with Nilo2 or with
Nilo2-mGNPs were blocked with 10% mouse serum in PBS
during 1 h at RT and stained with anti-Ha-FITC (1:100).
Alternatively, anti-Ha biotin (1:100) and streptavidin-A488
(1:400) or streptavidin-Texas Red (1:400) were used to amplify
the signal. Coverslips were mounted in DAPI/Mowioll and
analyzed in a Nikon Eclipse 80 i fluorescence microscope or a
LEICA TCS-SP2-AOBS confocal microscope.
For in vivo identification of Nilo2+ cells surrounding the brain
tumor, mice were intraperitoneally injected with Nilo2 ascites at
10 mg/g of body weight one week after the stereotaxic injection of
100 CT-2A cells. Next day, mice were euthanized and 25 mm
sections of fixed brains were analyzed using Cy5.5-labeled anti-
hamster antibody.
In neurosphere cultures incubated with EndoremTM, iron from
nanoparticles was reduced with acid solution of potassium
ferrocyanide and the blue pigment formed (Prussian Blue) was
detected with bright field microscopy.
Flow Cytometry
Single cell suspensions from neurospheres were obtained by
mechanical disaggregation. Unspecific antibody binding was
blocked with PBS, 10% mouse serum, 3% BSA, 0.0025% NaN3
for 30 min at 4uC. An excess of Nilo2-mGNPs coupled to
nanoparticles was added to the cell suspension and incubated for
1 h at 4uC. Cells with Nilo2 undiluted hybridoma were incubated
as a control. After PBS washes, cell suspensions were stained with
anti-Ha-FITC (1:100 diluted in PBS, 5% BSA, 0.025% NaN3).
Following additional PBS washes, cells were resuspended in 300 ml
cold PBS until FACS measurements (Epics XL, Coulter).
Propidium iodine was added (25 mg/ml) to each sample to gate
on living cells.
Results
Nilo2 Coupled to Magnetic Nanoparticles Identified
in vivo Neuroblasts in Neurogenic Niches
The monoclonal antibody Nilo2, recently developed and
characterized in our laboratory, was chosen for this study since
it identifies, in living cells surface, antigens on subventricular zone
(SVZ) neural precursors [35]. In fixed brain sections, double
stainings revealed that Nilo2+ cells were positive for neuroblast
markers and negative for neural stem cell markers (DCX+, PSA-
NCAM+, GFAP2 or SOX22) (Figure 1A). To ascertain whether
Nilo2 could be used for the in vivo identification of neuroblasts at
their niches, Nilo2 (0.25 mg) was intracranially injected into the
right striatum, mice were sacrificed 24 h after and the fixed tissue
was incubated with a secondary antibody recognizing hamster
IgG, to reveal binding of Nilo2 mAb. These experiments allowed
the identification of Nilo2+ cells either in the ipsi- or the
contralateral SVZ, with respect to the injection site (data not
shown), demonstrating that Nilo2 can identify its specific antigens
in vivo. In addition, stereotaxic transplantation of mouse GFP+CT-
2A cells generated an astrocytoma at the graft site in few days [40],
where the tumor cells could be identified as GFP+. Taking
advantage of the blood-brain barrier breakdown induced by the
brain tumor [41], Nilo2 mAb was intraperitoneally injected one
week after grafting the GFP+CT-2A cells and the animals were
sacrificed by transcardiac perfusion 24 hours later. Staining of
fixed brain tissue sections with an anti-Nilo2 fluorescent-labeled
secondary antibody revealed that the growing tumor mass was
surrounded by Nilo2 positive cells (Figure 1B). These cells were
further characterized as bona fide type I neuroblasts (neural
progenitors) since they were also positive for DCX and PSA-
NCAM (Figure 1C). Appearance of Nilo2+ cells surrounding the
tumor was concomitant with a strong reduction in Nilo2 staining
of the contiguous anterior horn of the lateral ventricle (white
arrowhead, Figure 1B). The presence of Nilo2+ cells at the damage
site, away from their niche, opened up the possibility to use this
mAb as a marker for in vivo analyses of endogenous neuroblasts in
pathophysiological conditions.
To explore the in vivo behavior of endogenous neuroblasts in
response to local brain damage, Nilo2 monoclonal antibody was
coupled to magnetic glyconanoparticles (Nilo2-mGNPs). This
approach allowed the in vivo identification of neuroblasts, following
their migration by magnetic resonance imaging (MRI). The
magnetic glyconanoparticles were composed of a magnetite core
covered by a gold shell bearing sugars and carboxyl-ending linkers
[36], to which protein G was coupled, allowing them to bind
antibodies (Figure 2). Magnetic glyconanoparticles were charac-
EndoremTM and mGNPs at different iron concentrations (top) allowed to estimate the transverse relaxation time constant T2* (bottom) represented
as mean 6 s.d. mGNPs (filled), EndoremTM (empty). C, Iron detection by Prussian blue staining on neurosphere cells preincubated with EndoremTM
nanoparticles; 136104 cells with 50 mg/ml Fe, (left) or 36104 cells with 5 mg/ml Fe (right). D, Representative coronal MRI views from a mouse brain
injected with iron-preloaded cells from (C) into the right lateral ventricle (low iron content) or into the left lateral ventricle (high iron content). The
images correspond to two different slices from the same brain. E, Cartoon representing Nilo2-mGNPs. F, Western blot of Nilo2-mGNPs suspension
used to estimate the amount of Nilo2 bound to mGNPs. Purified Nilo2 mAb (0.75 mg) was used as standard (lane 1). Different volumes (1–3 ml) of the
suspension were loaded on lanes 3–5. Lane 2 was empty. The amount of Nilo2 mAb bound to the mGNPs was estimated by densitometry (1.82 mg
Nilo2/mg Fe). G, Flow cytometry analyses of SVZ-derived neurosphere cells stained with Nilo2-mGNPs or Nilo2 alone, both revealed with a fluorescent
secondary antibody. H, Fluorescence microscopy of Nilo2-mGNPs labeled neurosphere cells (green) grown in Matrigel. I–K, In vivo identification of
neural precursors in mice intracranially injected with Nilo2-mGNPs (1 ml, 0.2 mg Nilo2 coupled to 0.11 mg Fe) either (I) contralaterally or (J, K)
ipsilaterally to the injection site. Since Nilo2 antibody had already been injected in vivo, the brain sections were incubated with a secondary
biotinylated anti-hamster Ig antibody and revealed with streptavidin-A488 (H–K) and analyzed by confocal microscopy. A scheme of the SVZ area
analyzed is shown. DAPI was used to stain nuclei (blue). Scale bars: A, 25 nm; C, H–K, 50 mm. LV, lateral ventricle; AH, anterior horn.
doi:10.1371/journal.pone.0044466.g002
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Figure 3. Nilo2-mGNPs allowed to reveal MRI hypointense signals in brain damage sites. A, Schematic representation of the injection
sites in the brain for the CT-2A astrocytoma cells (left hemisphere, d 0) and Nilo2-mGNPs (contralaterally in a more rostral position). B, Experiment
schedule, Nilo2-mGNPs injection day is indicated with an arrowhead, MRI acquisitions are shown with asterisks, before (empty) or after nanoparticle
injection (filled). C, Representative MRI analyses of mice injected with GFP-CT-2A cells (d 0) and either Nilo2-mGNPs (n = 4), or anti-human p53-mGNPs
(n = 4). Axial and coronal views on the day before (d+12), or either one (d+14) or five (d+18) days after nanoparticle injection. Arrowheads indicate the
hypointense signals at the tumor site. Arrows indicate the absence of hypointense signals in hp53-mGNPs injected mice at the tumor location. Mice
were sacrificed on day d+20. Insets in axial views from hp53-mGNPs and Nilo2-mGNPs injected mice show the signals due to nanoparticles at the
injection site. D, MRI tumor localization. T2 acquisitions showing the tumor localization on sections corresponding to the T2* MRI images shown in
(C). Tumor sites, defined by hyperintense signals are surrounded by a dotted line (white).
doi:10.1371/journal.pone.0044466.g003
Figure 4. Hypointense MRI signals at the tumor site correspond to neuroblasts. Immunohistochemical analyses of fixed brains from the
mice analyzed in Figure 3. A, Tissue sections from animals injected with Nilo2-mGNPs incubated with a fluorescent secondary antibody (left) or with
additional Nilo2 mAb (right) did not show differences neither in the number nor in the intensity of labeled cells (top). Confocal analyses confirmed
that the hypointense signals in the tumor site (T, GFP+ cells) correspond to neuroblasts (Nilo2+DCX+) (bottom). Inset, detail of the cell labeled by the
arrowhead. B, Specificity was shown on hp53-mGNPs injected mice using a fluorescent secondary anti-human p53 mAb, which did not reveal
migration of hp53-mGNPs-labeled cells (left), although Nilo2+ cells migrated towards the tumor (GFP+ cells) (right). Scale bars: 50 mm.
doi:10.1371/journal.pone.0044466.g004
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terized by transmission electron microscopy before and after
protein G coupling, measuring the size distribution (,6 nm
diameter) (Figure 2A). The Nilo2-mGNP complexes were highly
stable, monodisperse nanostructures with magnetic properties
comparable to commercial nanoparticles as revealed by phantom
analyses (Figure 2B). The minimal iron concentration that could
be detected with our MRI equipment was estimated from
phantom data as 0.5 mg/ml. Neurospheres pre-loaded with 50
or 5 mg/ml iron using EndoremTM nanoparticles (Figure 2C) were
grafted intra ventricles and subsequently detected by MRI, with
different hypointensities, depending on the iron concentration
(Figure 2D). From these data, a detection limit of #0.22 mg of iron
(right hemisphere) was estimated. Complexes Nilo2-mGNPs
contained 0.11 mg/ml of iron and 0.20 mg/ml of Nilo2 and the
mAb retained its specificity, since they identified in vitro cells from
neurosphere cultures (Figure 2E–H). In addition, Nilo2-mGNPs
identified in vivo Nilo2+ neural precursors in their neurogenic
niches after intracranial injection into the right hemisphere (1 ml of
Nilo2-mGNPs containing 0.20 mg Nilo2 and 0.11 mg iron)
(Figure 2 I-K) as uncoupled Nilo2 (0.25 mg, 1 ml) did. This was
Figure 5. Nilo2-mGNPs identify neuroblasts in the main neurogenic niches. A, Experimental schedule, Nilo2-mGNPs injection day is
indicated with an arrowhead, MRI acquisition days are shown with asterisks. B, Axial views at different rostrocaudal positions of a representative MRI
at different time points after the injection of PBS (1 ml, n = 2), Nilo2-mGNPs (n = 2) or CD3e-mGNPs (n = 2) into the right hemisphere in the absence of
tumor induction. Arrowheads indicate the hypointense signals in neuroblasts niches.
doi:10.1371/journal.pone.0044466.g005
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Figure 6. Migration kinetics of Nilo2-mGNPs labeled cells in response to damage. A, Experimental schedule, Nilo2-mGNPs injection day is
indicated with an arrowhead, MRI acquisition days are shown with asterisks, day 0 represents the day in which the CT-2A injury was generated.
Asterisk on day 20 indicates an ex-vivo MRI of fixed brain before immunohistochemical analysis. B, Axial, coronal and sagittal views of a representative
MRI one day before (d21), or one (d+1) to18 (d+18) days after the injection of tumor cells in the left hemisphere (n = 6) showing the Nilo2-mGNPs
injection site (Nilo2-mGNPs site) and CT-2A injection site (CT-2A site). Arrowheads indicate the hypointense signals detected at the tumor vicinity. C–
E, Axial MRI acquisitions from three additional mice, the day before (d21), one (d+1), four (d+4) or 18 (d+18) days after tumor cell injection.
doi:10.1371/journal.pone.0044466.g006
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shown by staining fixed brain sections from these mice sacrificed
one day after surgery, with an appropriate secondary antibody.
Brain Tumors Induce Endogenous Neuroblast Migration
The CT-2A astrocytoma was chosen as a model due its high
reproducibility on tumor development. GFP+CT-2A cells were
grafted into the mice brain left hemisphere by stereotaxic surgery.
These cells generated a tumor over the following 10–12 days
(Figure 1B, and Figure 3). At this time point, Nilo2-mGNPs were
stereotaxically injected in a more rostral position of the right
hemisphere and contralaterally to the tumor site, without any
detectable ventricle damage. Comparison of the T2* MRI
measurements the day before (d+12) and the day after Nilo2-
mGNPs injection (d+14) showed the appearance of hypointense
signals (black dots) at the tumor graft site (arrowheads in
Figure 3C), which were undetectable before nanoparticles
injection (d+12), although at this time-point the T2 images
indicated that the tumor was already formed (Figure 3D). In
addition, hypointense signals also appeared in both the cerebro-
spinal fluid and the lateral ventricle walls (Figure 3C, d+14). These
hypointense signals increased in the region surrounding the
damage site with time. Black spots in the left lateral ventricle
(d+14 in Figure 3C) reached the tumor site (arrowhead, coronal
view on Figure 3C) four days later (d+18 in Figure 3C), indicating
an accumulation of Nilo2-mGNPs at the tumor site concomitant
with tumor growth (hyperintense signals in Figure 3D). The
hypointense signals detected by MRI at the nanoparticles injection
site show that both Nilo2-mGNPs and hp53-mGNPs were injected
at the striatum (insets Figure 3C). The nanoparticles were not in
direct contact with the cerebrospinal fluid, thus minimizing the
passive diffusion effects. A control mAb (anti-human p53) coupled
to the same mGNPs failed to generate a signal at the tumor
vicinity (arrow) or within the ventricles, although the T2 MRI
signals demonstrated that the tumor was formed (Figure 3C, D).
Unlike Nilo2-mGNPs, hp53-mGNPs were exclusively detected at
the injection site (Figure 3C), indicating that the migration
specificity of the Nilo2-mGNPs was given by the Nilo2 mAb. To
confirm that the MRI signals corresponded to Nilo2-mGNPs,
mice were then sacrificed (d+20 in Figure 3B) and the fixed brain
sections directly labeled with an anti-Nilo2 secondary fluorescently
labeled antibody. These analyses allowed to verify that the MRI
hypointense signals surrounding the tumor site corresponded to
Nilo2+ cells (Figure 4A). The Nilo2+ cells surrounding the GFP-
tumor were also DCX+ cells (Figure 4A), indicating that they
correspond to bona fide neuroblasts. These results have been
confirmed by additional stainings of Nilo2-mGNPs in vivo together
with DCX (see below Figure 7C–G). When these tissue sections
were incubated with additional Nilo2 mAb, we failed to detect an
increase of the number of Nilo2+ cells, suggesting that most of the
neuroblasts were already labeled with Nilo2-mGNPs. Immuno-
histochemical analyses corroborated that hp53-mGNPs remained
undetectable either at the vicinity of the tumor or scattered
through the parenchyma (Figure 4B), although it was still detected
by MRI at its injection site (Figure 3C). It should be noted that in
the hp53-mGNPs injected animals, neuroblasts surrounded the
tumor as shown by the staining with Nilo2 mAb (Figure 4B).
Aiming to favor recognition of the neuroblast niches by the
Nilo2-mGNPs, the immunonanoparticles were injected into right
SVZ before tumor induction, without any detectable ventricle
damage. Indeed, in these mice hypointense signals in the principal
neurogenic niches were detected, which were stable during 26
days in the absence of tumor (Figure 5). Conversely, mice injected
with the same volume of PBS failed to produce any hypointense
signal due to hemorrhage (Figure 5B, d+2 to d+14). Specificity was
corroborated using mGNPs coupled to an isotypic control anti-
mouse CD3e hamster mAb, where the detectable MRI signals
were restricted to the SVZ injection site, even 26 days after
injection (Figure 5B, d+2 to d+26). These data allowed to discard
that appearance of hypointense signals surrounding the tumor in
Nilo2-mGNP injected animals were due to passive diffusion of the
nanoparticles. In the presence of tumor induction due to the graft
of CT-2A cells, 72 h after the injection of Nilo2-mGNPs, results
comparable to the ones shown in Figure 3 were obtained
(Figure 6A). Indeed, in these experiments, Nilo2-mGNPs labeled
the neuroblast niches, as demonstrated by MRI analyses preceding
the graft of the tumor cells. Furthermore, hypointense signals near
the damage site were detected by MRI as soon as 24 h after tumor
injection (arrowheads, Figure 6, d+1). These hypointense signals
increased and accumulated surrounding the tumor (Figure 6B, C)
and corresponded to endogenous Nilo2+ DCX+ cells (Figure 7).
These cells migrated from the lateral ventricles through different
structures including the highly dense corpus callosum (CC)
(Figure 7A, B). In addition, Nilo2-mGNPs identified bona-fide
neuroblasts in subependymal patches on the lateral ventricle and
the anterior horn of the contralateral ventricle with respect to
tumor localization, since all the Nilo2+ cells were also DCX+
(Figure 7C–G). Immunohistochemical analyses on fixed brain
sections from MRI-analyzed animals corroborated that Nilo2
mAb remained coupled to the mGNPs in vivo for at least 23 days,
as shown by the co-localization of the nanoparticles with Nilo2
(Figure 7H–J). In tissue sections from these animals, Nilo2-mGNP+
cells were co-stained with specific antibodies recognizing glial cells
(GFAP), activated microglia cells (CD11b) or T lymphocytes
(CD4, CD8). The absence of double stained cells allowed to
formally exclude that the hypointense signals surrounding the
tumor were due to cells that, after unspecifically engulfing the
Nilo2-mGNPs, migrated to the damage site (Figure 7K–O), in full
agreement with the experiments using hp53 or CD3e control
antibodies coupled to the mGNPs (see above).
Migration of Neural Precursors Starts in a Few Hours, is
Fast and Orderly
From these MRI experiments, migration rates were estimated in
150 mm/h, and were equivalent to the migration rates (less than
24 h) detected for exogenous GFP+-neurosphere-derived cells
following brain injury (Figure 8). The position of the tumor graft
determined the time for Nilo2-mGNP-labeled cells to reach the
damage site, increasing in grafts localized in more lateral positions
(Figure 6E, d+4). Further MRI analyses on animals where Nilo2-
mGNPs were injected before contralaterally grafting CT-2A
tumor cells revealed the detection of the first hypointense signals
in the tumor region as early as five hours after graft injection,
resulting on an estimated migration rate of 700 mm/h. These
signals were maintained for at least 27 hours, where the presence
of Nilo2+ cells around the CT-2A tumor was confirmed by
immunohistochemistry (Figure 9). We also detected additional
Nilo2+ cells in the corpus callosum and the area between this
structure and the tumor (Figure 9C). Since Nilo2+ cells in wild-type
animals are mostly restricted to their niche in the lateral ventricle
[35], their presence in the highly dense corpus callosum, together
with their morphology with elongated nuclei and cytoplasmic
projections [42,43], reinforce the notion that these cells represent
actively migrating neuroblasts from their niche towards the
damage site induced by the tumor.
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Figure 7. Nilo2-mGNPs specifically label Nilo2+ neuroblasts migrating towards the tumor site. A, B, Immunohistochemical analyses of
the brain from Figure 6B with a fluorescent secondary antibody demonstrating the migration of Nilo2+ cells (red) towards the tumor area (GFP+) (A),
or migrating from the contralateral ventricle through the RMS and the CC (B). C–G, The complexes Nilo2-mGNPs targeted Nilo2+ DCX+ cells in the
contralateral ventricle to the tumor site (C), in subependymal positions of the lateral ventricles (D) or surrounding the GFP-CT-2A tumor (green) (E–
G). H, Bright field microscopy showing nanoparticles in black. I, Nilo2 mAb coupled to mGNPs was revealed with a fluorescent secondary antibody
(red). J, Merge from (H) and (I) indicating that Nilo2 mAb was still coupled to the mGNPs 23 days after intracranial injection. K–O, Nilo2-mGNPs were
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not engulfed by astrocytes (GFAP+), microglia (CD11b+) nor T lymphocytes (CD4+, CD8+). Mice were injected with Nilo2-mGNPs (K) in the absence or
(L–O) in the presence of GFP-CT-2A tumor cells (green). DAPI was used to stain nuclei. Scale bars: A, B, 50 mm; H–M, O, C, 45 mm; N, D–G, 20 mm.
LV, lateral ventricle; CC, corpus callosum; RMS, rostral migratory stream.
doi:10.1371/journal.pone.0044466.g007
Figure 8. Exogenous GFP+ neural precursors migrated to the damage site in less than 24 hours. A–F, control or G–M, CT-2A injected
animals were subsequently injected by stereotaxic surgery with SVZ-derived GFP+-neurosphere cells in the contralateral striatum. Mice were sacrificed
24 hours after injection of the CT-2A cells and brain tissue sections were analyzed by either (A–D, G–J) stereo microscopy or (E, F, K–M) confocal
microscopy. Migrating GFP+ cells in (B, H) cortex; (D, E) injection site of neurosphere cells; (C, E, F) in CC; (I, K, L) injection site of tumor CT-2A cells;
(J, M) CC in a caudal position respect to both injection sites. Scale bars: E, F, 150 mm; K, L, 50 mm; M, 75 mm.
doi:10.1371/journal.pone.0044466.g008
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Discussion
The monoclonal antibody Nilo2 was described as recognizing
surface antigens from mouse type I neuroblasts and in immuno-
histochemistry identifies cells within the anterior horn of the lateral
ventricle [35]. We have substantiated these data and in addition
we show that Nilo2 mAb is able to identify these cells in vivo,
following intracranial injection of the antibody. We confirmed the
identity of the labeled cells in vivo by immunohistochemistry with
other neuroblast type I markers such as DCX and PSA-NCAM.
Our data also show that following the local injection of CT-2A
cells, which generated an astrocytoma at the graft site, Nilo2+ cells
could be detected surrounding the tumor. As the detection of
Nilo2+ cells surrounding the tumor was concomitant with a strong
reduction in their number in the contiguous lateral ventricle niche,
suggested that Nilo2+ cells might migrate from their niche towards
the tumor graft site. This allowed us to envisage the possibility of
using this mAb as a marker for endogenous neuroblast migration
analyses in living animals. The concept of endogenous neuroblasts
migrating in response to damage, although not formally demon-
strated yet, had been already suggested on the basis of
immunohistochemistry and MRI analyses using transplanted cells.
Indeed, a strong tropism of neural precursors for glioblastomas has
been described in mice [22,44]. In addition to the migration ability
of exogenous precursors, some studies demonstrated it for
endogenous neural precursors. For example, using a nestin-GFP
transgenic, Glass et al. [44] have shown, in a murine experimental
glioblastoma model, that nestin+ cells originating in the subven-
tricular zone migrated towards the tumor vicinity within 4–14
days. These cells were ki67+, mushashi+, NG-2+, GFAP+, PSA-
NCAM+ or DCX+, indicating the migration of committed and
noncommitted precursors. The absence of unique cell surface
markers for neural stem cells or for neuroblasts has impaired the in
vivo study of particular cell phenotypes migration. Our data show
that by combining the mAb Nilo2 with magnetic glyconanopar-
ticles (Nilo2-mGNPs), the Nilo2 mAb in vivo zeroed in the
complexes on neuroblasts, allowing the selective tracking of
endogenous neuroblast progenitors in vivo by MRI. Indeed,
Nilo2-mGNPs identified neuroblasts within their niches in the
absence of additional damage. In addition, following injection of
CT-2A cells, it also identified neuroblast cells surrounding the
tumor, as demonstrated by MRI and confirmed by immunohis-
tochemistry. The obtained MRI patterns were specific for Nilo2,
since both anti-hp53 and anti-mouse CD3e conjugated to the
same mGNPs failed to show signals on neuroblast niches or
surrounding the CT-2A tumor. In addition, confocal microscopy
showed that the Nilo2-mGNP complexes remained intact in vivo
for at least 23 days.
Complementary experiments in which, Nilo2-mGNPs were
contralaterally injected after generating a tumor, or in which
Nilo2-mGNPs were injected first (favoring binding of the mGNPs
to Nilo2+ cells in their niches), both gave similar results, namely
that Nilo2-mGNPs were detected surrounding the tumor cells after
a short time-period. In addition, in grafts localized in more lateral
positions, the time for the Nilo2-mGNP-labelled cells to reach the
damage site increased. Interestingly, in experiments where binding
of the Nilo2-mGNPs to neuroblasts in their niches was favored,
MRI experiments demonstrated a continuous accumulation of
Nilo2+ cells, starting as early as 5 h following injection of the CT-
2A cells. Furthermore, Nilo2+ cells with migrating cell morphology
(elongated nuclei and cytoplasmic projections) were detected in the
corpus callosum at short times. Taken together, these data indicate
that the accumulation of type I neuroblasts (Nilo2+) surrounding
the tumor cells is due to an orderly migration of these cells from
Figure 9. Endogenous Nilo2+ cells migrate fast and orderly in
response to a tumor. Nilo2-mGNPs were injected into the right
hemisphere and CT-2A cells into the left striatum four days later (n = 8).
A, Nilo2+ cell migration was analyzed using MRI before (0 h), 5 h, 20 h
and 27 h after CT-2A injection. Arrowhead and arrow on each panel
show the positions of the hypointense signals after injection of the
tumor cells (5 h, 20 h and 27 h), and the lack of hypointense signals
before injection of the tumor cells (0 h). Control MRI analyses before the
injection of the Nilo2-mGNPs (no particles) and injection site of these
complexes at 0 h were included. B, C, Immunohistochemical analyses
were performed after the last MRI at 27 h. Some of the migrating cells
had already reached the tumor injection site (T), whereas others were
still migrating through the CC. Nuclei were stained with DAPI (blue).
White arrow in (B) indicates the magnified region in the inset. Scale
bars: B, 75 mm; inset in B, 10 mm; C, 50 mm.
doi:10.1371/journal.pone.0044466.g009
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their brain niches (estimated speed range 150–700 mm/h) towards
the lesion site, implying a fast damage response (less than 24 h),
rather than to migration of brain-scattered neuroblasts or being
the result of cell de-differentiation. The migration occurred either
tangentially with a rostrocaudal pattern, throughout the entire
SVZ, or in a radial pattern through the parenchyma at the
contralateral hemisphere that crosses the high-dense structures of
the corpus callosum.
In contrast to previous reports using in situ injection of a high
concentration micron-sized iron oxide particles (MPIO) [17], and
where only a small percentage of the migrating neuroblasts were
labeled [15,16], in this work, where a monoclonal antibody was
coupled to the contrast agent, most of the resident neuroblasts
were labeled without cellular damage and detected by MRI, even
using a reduced amount of nanoparticles (0.11 mg Fe/mouse). It
should be noted that the amount of Nilo2 used (0.20 mg Nilo2/
mouse) is at least 60 times less than the minimal amount in which
an effect on either neurosphere proliferation or differentiation
in vitro could be detected [35]. These data support the notion that
Nilo2 mAb zeroed in the mGNPs on neuroblast type I cells, which,
as a consequence of a localized damage migrated labeled with
Nilo2-mGNPs.
To exclude that some of the hypointense signals detected by
MRI were background signals due to inflammation, iron
accumulation due to hemorrhage or tumor growth, we included,
in addition to controls with irrelevant antibodies coupled to the
mGNPs (anti-hp53, anti-mouse CD3e) or PBS injection, appro-
priate controls for each animal, namely the MRI data of the same
animal prior to Nilo2-mGNP injection in the contralateral
hemisphere (i.e. d+12 in Figure 3).
These data allowed us to envisage that neuroblast migration in
response to a brain tumor might represent an attempt to repair the
damaged tissue [42,44]. In the CT-2A model used on this work,
however, the fast tumor evolution (mice died within four weeks)
hampered any possible benefit of the migrating neuroblasts.
Preliminary data on epilepsy models (G.E. unpublished results)
suggest that neuroblast migration in response to damage is not
restricted to this tumor model, since it also takes place following
active peaks in some neurodegenerative diseases, opening up the
possibility of using neuroblast migration for the early detection of
brain lesions in neurodegenerative diseases where a link between
damage with the etiopathology has not yet been fully established.
In fact, this correlation could have strong implications in the
prognosis and treatment of these diseases. Moreover, we have
already demonstrated that other Nilo monoclonal antibodies had
the ability to target nanoparticles to a particular cell subpopulation
[45]. Fluorescent-magnetic glyconanoparticles conjugated to
appropriate antibodies have been shown to specifically tag minor
population of leucocytes (0.01%) in the whole human blood [37].
Thus, the use of nanoparticles is not necessarily restricted to the
nervous system and could be used for locating minor populations
such as stem cells in their niches, identification of cancer stem cells,
or tracking migration of other cell types in the body, including
metastatic cells.
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